Britain’s next major review of medical-cannabis policy is supposed to answer a deceptively simple question: did the 2018 law change have the intended effect?
The Government told Parliament on 1 June that the Advisory Council on the Misuse of Drugs report was expected in summer 2026. As of 27 July, the new report had not appeared on the relevant GOV.UK publication pages checked by The Ganja Club.
That is not evidence of a delay; “summer” is not over. It is a reason to examine the standard by which the report should be judged when it arrives.
The question cannot be answered by saying that cannabis-based products for medicinal use became legal to prescribe. Legal availability is an input. The outcomes are whether patients can reach appropriate treatment, whether products are safe and consistent, whether prescribing is well governed, and whether the system is producing evidence strong enough for wider NHS use.
What the ACMD has been asked to review
The Home Office commissioned the work in June 2025, nearly seven years after the 2018 rescheduling.
The ACMD was asked to assess whether the legislation had its desired impact and to identify unintended consequences. One issue was named explicitly: whether access through private prescriptions has reduced the incentive to run trials that could produce safe, effective and cost-effective products for the NHS.
That wording matters. It acknowledges the unusual system that developed after reform. Private prescribing expanded while routine NHS access remained exceptionally narrow. Patients gained a legal route, but usually only if they could pay.
The council subsequently opened a call for evidence to patients and families, clinicians, researchers, manufacturers, importers, regulators and enforcement bodies. The breadth of that invitation suggests the review is intended to look beyond pharmacology.
Test one: access, measured honestly
The review should separate legal access from practical access.
Useful measures include the number of NHS and private prescriptions, regional variation, conditions treated, waiting times, discontinuation rates and the full cost to patients. A national total without those breakdowns could conceal a system concentrated among people able to afford repeated consultations and monthly medication.
It should also examine what happens before a prescription. Do patients receive a clear explanation of licensed alternatives, uncertainty, impairment and driving law? Are eligibility decisions consistent? Can people obtain follow-up when a product is unavailable or poorly tolerated?
Patient numbers are relevant, but they are not a quality measure on their own.
Test two: the NHS evidence bottleneck
The commission is right to ask whether private access has changed incentives for trials. The answer needs more than blaming patients or clinics for using the legal route available to them.
Unlicensed products can vary in cannabinoid profile, formulation and supply. Randomised trials are expensive, and a manufacturer may have limited commercial incentive to fund medicine-level research if products can already be prescribed privately. Researchers also face recruitment, placebo, blinding and standardisation challenges.
The review should identify which barriers are regulatory, which are commercial and which arise from trial design. It should recommend who is responsible for fixing each one.
That could include public funding for priority questions, access to standardised study products, core outcomes that allow trials to be compared and a clearer route from a positive result to health-technology assessment and NHS commissioning.
Calling for “more evidence” without building that route would repeat the problem.
Test three: prescribing quality and conflicts
The growth of a private market makes governance central.
The review should examine prescribing volumes by provider and prescriber, follow-up intervals, adverse-event reporting, pharmacy relationships, advertising, financial incentives and the management of product shortages. It should look for both under-treatment and prescribing that is not sufficiently individualised.
This is not an argument that private care is inherently poor. Many patients report thoughtful clinical support after exhausting conventional options. It is an argument that a system relying heavily on private provision needs transparent, comparable standards.
Separation between clinical decisions and commercial pressure should be visible, not assumed.
Test four: product quality and continuity
A prescription is only useful if the prescribed product is available, affordable and consistent.
Patients have repeatedly described substitutions, stock changes and the need to adapt to a different formulation or flower. The review should assess how often that occurs, how changes are communicated and whether current import and supply rules create avoidable instability.
It should also distinguish products with marketing authorisation from unlicensed cannabis-based products and explain what quality evidence applies to each category. That distinction is poorly understood outside specialist circles and is frequently blurred in public discussion.
Test five: patients’ lives outside the clinic
The consequences of prescribing extend into driving, employment, housing, travel and policing.
A person can hold a lawful prescription and still face uncertainty when a drug test detects THC. Employers may focus on presence rather than impairment. Police encounters can depend on whether documentation is available and understood. International travel can turn lawful treatment into a border problem.
The ACMD’s remit is not identical to that of every agency involved, but a review of “unintended consequences” should map these frictions and name the department responsible for each response.
The law change cannot be called successful if legality exists mainly on paper and patients must repeatedly prove it to institutions that have not adapted.
What a useful report would recommend
The strongest report would give Government a sequence, not a wish list.
Immediate actions could include consistent prescribing and adverse-event data, clearer patient documentation, minimum expectations for drug-testing and occupational-health review, and published responsibilities during product shortages.
Medium-term actions could include publicly funded comparative trials in priority conditions, agreed outcome sets and a defined NHS adoption route for products that meet evidence and cost-effectiveness thresholds.
Longer-term recommendations should address whether the present scheduling and unlicensed-products framework remains the best mechanism for balancing access, research and control.
Each recommendation should have an owner, a timetable and a measure of success. Without those, even a rigorous review risks becoming another description of a gap everyone already recognises.
The editorial view
The 2018 reform was neither meaningless nor complete. It gave patients a legal route that did not exist before. It also produced a two-speed system in which private access advanced far beyond NHS availability.
The ACMD should resist two easy narratives: that rising private prescriptions prove the policy worked, or that limited NHS prescribing proves cannabis medicine has failed. Both confuse the performance of the system with the efficacy of every product.
The right question is whether Britain has built a pathway that turns lawful access into better evidence, safer care and fairer availability. Nearly eight years after rescheduling, the review should be precise enough to show what must change next.
Key takeaways
- The Government told Parliament the ACMD report was expected in summer 2026.
- As of 27 July, the new report had not appeared on the relevant GOV.UK pages checked by The Ganja Club.
- The commission asks whether the 2018 legislation worked and whether private prescribing has affected incentives for NHS-oriented trials.
- A credible review must measure affordability, prescribing quality, product continuity and patients’ experiences beyond the clinic.
- Recommendations need named owners, deadlines and measurable outcomes.
